Esperion Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
momentum, announcing a planned acquisition of Corstasis to gain global rights to Enbumyst , an FDA-approved intranasal loop diuretic; the deal is expected to close in Q2 2026 and is intended to create two cardiovascular franchises. Financially, Esperion reported Q4 revenue of $168.4 million (up 144% year-over-year ), driven by $124.7 million in collaboration revenue (including a $90 million Otsuka payment) and U.S. net product revenue of $43.7 million (up ~38%), ending 2025 with $167.9 million in cash and reduced debt. On the pipeline and outlook, Esperion is advancing triple-combination bempedoic acid+ezetimibe+statin programs targeting commercialization in , nominated ESP-2001 for primary sclerosing cholangitis with clinical entry planned by end of 2026, and provided 2026 operating expense guidance of $225–$255 million. Interested in Esperion Therapeutics, Inc.? Here are five stocks we like better. Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company del
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines [Yahoo! Finance]Yahoo! Finance
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session [Yahoo! Finance]Yahoo! Finance
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific SessionGlobeNewswire
- Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of DyslipidemiaGlobeNewswire
- Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 3/10/26 - Miss
ESPR
Sec Filings
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- ESPR's page on the SEC website